Nature Cancer

Article	Citations
Enhancing childhood cancer targetability	710
Shooting for multiplexed pathology with Orion	537
Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial	508
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer	411
An oncolytic circular RNA therapy	373
Considering molecular alterations as pan-cancer tissue-agnostic targets	330
A low-coverage liquid biopsy for lung cancer	325
Author Correction: Breaking the performance ceiling for neoantigen immunogenicity prediction	308
Author Correction: Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling	291
Author Correction: IL-17A-secreting γδ T cells promote resistance to CDK4/CDK6 inhibitors in HR+HER2− breast cancer via CX3CR1+ macrophages	271
Author Correction: RIOK1 phase separation restricts PTEN translation via stress granules activating tumor growth in hepatocellular carcinoma	248
Evolutionary trajectories of IDH-mutant astrocytoma identify molecular grading markers related to cell cycling	208
The cGAS–STING pathway and cancer	193
ZFP281 drives a mesenchymal-like dormancy program in early disseminated breast cancer cells that prevents metastatic outgrowth in the lung	181
Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80	180
The proteasome regulator PSME4 modulates proteasome activity and antigen diversity to abrogate antitumor immunity in NSCLC	156
Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial	153
MALAT1 protects dormant tumor cells from immune elimination	148
A macrophage-activated abscopal effect	147
Breaking frontiers with multidisciplinary cancer research	140
PARP11 interfer(on)es with CAR T cell efficacy	136
Gut decisions in CAR T cell therapy	135
Single-cell transcriptomic landscape deciphers olfactory neuroblastoma subtypes and intra-tumoral heterogeneity	132
A single-cell map of dynamic chromatin landscapes of immune cells in renal cell carcinoma	131
Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms	129

Palmitate oxidation drives a pro-metastatic post-translational modification	123
Expanding the options for KRAS inhibition	123
Reply to: Ricolinostat is not a highly selective HDAC6 inhibitor	119
crossNN is an explainable framework for cross-platform DNA methylation-based classification of tumors	119
IKAROS and MENIN coordinate therapeutically actionable leukemogenic gene expression in MLL-r acute myeloid leukemia	117
The importance of being generous	115
Advancing therapeutics in small-cell lung cancer	115
Shaping the microenvironment in peritoneal metastases	113
Stress granules shape metabolic reprogramming and drug resistance	108
A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma	108
Bone marrow progenitor-like cells against leukemia cure	108
Impact of context-dependent autophagy states on tumor progression	107
Targeting PRMT9-mediated arginine methylation suppresses cancer stem cell maintenance and elicits cGAS-mediated anticancer immunity	107
Adoptively transferred tumor-specific IL-9-producing cytotoxic CD8+ T cells activate host CD4+ T cells to control tumors with antigen loss	106
A molecular glue halts RAS–MAPK signaling	106
Determinants of resistance and response to melanoma therapy	106
Innate immunity drives epithelial cell plasticity during prostate tumor formation	105
Sarcoma ecotypes determine immunotherapy benefit	104
A tumor-derived metabolite primes the leptomeningeal pre-metastatic niche	103
Antibody avidity meets multiple myeloma	103
Thriving in diverse ecosystems	99
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer	99
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma	98
Evolving landscape of nasopharyngeal carcinoma therapy	95
Cancer-derived mitochondria fuel fibroblasts to become pro-tumorigenic	94
Key insights from ESMO Congress 2025	92
Inflammation meets translation in AML	91
Sex-specific gut microbiota and neutrophil senescence in bladder cancer	91
A comeback for checkpoint inhibition in multiple myeloma	89
SCRN1 confers hepatocellular carcinoma resistance to ferroptosis by stabilizing GPX4 via STK38-mediated phosphorylation	88
Cycling back to folate metabolism in cancer	86
Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes	84
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling	82
Circadian regulation of cancer stem cells and the tumor microenvironment during metastasis	82
Integrative single-cell analysis of human colorectal cancer reveals patient stratification with distinct immune evasion mechanisms	82
Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer	81
Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers	80
INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas	80
Clinical implementation of artificial-intelligence-assisted detection of breast cancer metastases in sentinel lymph nodes: the CONFIDENT-B single-center, non-randomized clinical trial	79
A multiomic atlas identifies a treatment-resistant, bone marrow progenitor-like cell population in T cell acute lymphoblastic leukemia	79
MCL1 inhibitor BRD-810 kills cancer cells while minimizing risk of cardiotoxicity	78
Regulatory T cells play a crucial part in radio-immunotherapy resistance of brain tumors	78
Radioligand cancer therapy comes to the fore	77
Immunosuppressive dura-derived macrophages in leptomeningeal metastasis	77
Author Correction: Ectopic JAK–STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance	76
CHD1 status drives divergent metabolic pathways in SPOP-mutant prostate cancer	76
Multimodal data integration improves immunotherapy response prediction	76
Dual inhibition of EGFR and PI3K with a single drug	76
First-in-class ultralong-target-residence-time p38α inhibitors as a mitosis-targeted therapy for colorectal cancer	75
Immunotargeting of a recurrent AML-specific neoantigen	75

Concurrent inhibition of tumor growth and metastasis by a lipidated nanophotosensitizer tracing and disabling tumor extracellular vesicles	74
Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial	74
Building a translational cancer dependency map for The Cancer Genome Atlas	74
Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping	74
A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes	73
Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages	70
Selective targeting of malignant T cells	70
PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma	70
How AI agents will change cancer research and oncology	70
Highlights from the 2025 ASCO Annual Meeting	69
AKTing on XPO1 inhibition in AML	69
Bispecific chimeric T cell receptors tackle tumor heterogeneity	68
The dopamine transporter antagonist vanoxerine inhibits G9a and suppresses cancer stem cell functions in colon tumors	68
Regional delivery of hypoxia-responsive CAR T cells improves efficacy for solid tumors	68
Protein-level mutant p53 reporters identify druggable rare precancerous clones in noncancerous tissues	68
BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models	66
Single-cell analysis and functional characterization uncover the stem cell hierarchies and developmental origins of rhabdomyosarcoma	66
Threonine fuels glioblastoma through YRDC-mediated codon-biased translational reprogramming	65
Identification of a clinically efficacious CAR T cell subset in diffuse large B cell lymphoma by dynamic multidimensional single-cell profiling	62
Advances in antibody-based therapy in oncology	62
The pro-oncogenic noncanonical activity of a RAS•GTP:RanGAP1 complex facilitates nuclear protein export	61
Single-cell analyses implicate ascites in remodeling the ecosystems of primary and metastatic tumors in ovarian cancer	61
Single-cell meta-analyses reveal responses of tumor-reactive CXCL13+ T cells to immune-checkpoint blockade	61
The tumor microenvironment’s role in the response to immune checkpoint blockade	60
Anything to declare?	60
Epigenetic plasticity in PDAC	59
An antisense RNA promotes breast cancer metastasis via upregulation of NQO1	58
Metabolic symbiosis in pancreatic cancer	58
There are gremlins in prostate cancer	57
Estrogen receptor-positive breast cancer subtypes show differential macrophage functions	57
Ricolinostat is not a highly selective HDAC6 inhibitor	57
An unexpected career in cancer metabolism	57
In vivo macrophage engineering for renal cancer therapy	56
P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia	55
Author Correction: An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia	55
Author Correction: Anti-CTLA-4 antibodies drive myeloid activation and reprogram the tumor microenvironment through FcγR engagement and type I interferon signaling	54
Author Correction: Autotaxin–lysolipid signaling suppresses a CCL11–eosinophil axis to promote pancreatic cancer progression	54
Author Correction: Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation	54
Neoadjuvant immunotherapy marks a new era in oncology	53
Targeting ADAR1 with a small molecule for the treatment of prostate cancer	53
Dual modulation of cytotoxic and checkpoint receptors tunes the efficacy of adoptive Delta One T cell therapy against colorectal cancer	52
M-PACT leverages cell-free DNA methylomes to achieve robust classification of pediatric brain tumors	52
Tumor evolution metrics predict recurrence beyond 10 years in locally advanced prostate cancer	52
Innate immunity and the NF-κB pathway control prostate stem cell plasticity, reprogramming and tumor initiation	52
Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapy	52
p53 at the crossroads of tumor immunity	51
Myeloma evades T cell-engaging therapies	50
Sarcoma microenvironment cell states and ecosystems are associated with prognosis and predict response to immunotherapy	50
A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets	50
Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p	49
Clinical and translational attributes of immune-related adverse events	49
Understanding the biology of lung cancer brain metastases	49
Mitochondrial DNA mutation enhances sensitivity to immunotherapy in melanoma	49
Author Correction: Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome	48
Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial	48
Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses	48
Breaking the performance ceiling for neoantigen immunogenicity prediction	48
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors	47
CD8+ T cell killing of MHC class I–deficient tumors	47
Masking T cell engagers mitigates on-target off-tumor activity	46
Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors	46
CAR T cell therapy: looking back and looking forward	46
UnitedMet harnesses RNA–metabolite covariation to impute metabolite levels in clinical samples	46
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma	45
PD-L2 expression in senescent cancer cells limits tumor clearance after chemotherapy	44
Overcoming extracellular vesicle-mediated fratricide improves CAR T cell treatment against solid tumors	43
Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis	43
Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment	42
FLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapy	42
Unique structural configuration of EV-DNA primes Kupffer cell-mediated antitumor immunity to prevent metastatic progression	42
CD103+ regulatory T cells underlie resistance to radio-immunotherapy and impair CD8+ T cell activation in glioblastoma	42
Tumor-intrinsic sensitivity to the pro-apoptotic effects of IFN-γ is a major determinant of CD4+ CAR T-cell antitumor activity	42
TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation	42
Communicating with respect	41
The meaning of impact	41
Global loss of promoter–enhancer connectivity and rebalancing of gene expression during early colorectal cancer carcinogenesis	40
Radiopharma pipeline builds ahead of key data	40
Efficacy and tolerability of neoadjuvant therapy with Talimogene laherparepvec in cutaneous basal cell carcinoma: a phase II trial (NeoBCC trial)	39
Spatially resolved transcriptomics and graph-based deep learning improve accuracy of routine CNS tumor diagnostics	39
Glucagon-like peptide-1 medicines and cancer	39

Genomic and immune signatures predict clinical outcome in newly diagnosed multiple myeloma treated with immunotherapy regimens	38
Near-infrared optogenetic engineering of bacteria for cancer therapy	38
EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance	38
Cellular neighborhoods in cancer	38
Leveraging the potential for deintensification in cancer care	37
CD4+ CAR T cells — more than helpers	37
Insight from the ESMO Targeted Anticancer Therapies Congress 2025	37
Acute lymphoblastic leukemia displays a distinct highly methylated genome	37
Targeted inhibition of FBXL2 confers susceptibility of HER2-negative breast cancer to trastuzumab deruxtecan	37
A 180 degree turn en route to crafting a scientific career that never goes stale	37
Disparities, aging and childhood cancer	36
Tucatinib–trastuzumab–capecitabine for treatment of leptomeningeal metastasis in women with HER2+ breast cancer: TBCRC049 phase 2 study results	36
Artificial intelligence for prostate cancer diagnostics	36
Commensal metabolite boosts chemotherapy	36
Leptomeningeal metastatic cancer cells induce a permissive choroid plexus vasculature through extracellular-vesicle-derived 5-HIAA signaling	36
SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors	36
Leveraging translational insights toward precision medicine approaches for brain metastases	36
Antibiotic-related dysbiosis in cancer immunotherapy: from preclinical insights to practice-changing evidence	35
Author Correction: Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy	35
‘IL-2Rα-biased’ IL-2 for cancer immunotherapy	35
Author Correction: Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial	35
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells	34
The aging lung reawakens dormant tumor cells	34
Clinical outcomes with perioperative nivolumab by nodal status in patients with stage III resectable NSCLC: phase 3 CheckMate 77T exploratory analysis	34
Targeting HIF-1 to treat AML	34
CDK10 inhibits innate sensing to constrain antitumor immunity	34
Harnessing foundation models for digital pathology without re-training	34
Fibrotic tumors tune metabolism for immune evasion	33
Cytidine deaminases APOBEC3C and APOBEC3D promote DNA replication stress resistance in pancreatic cancer cells	32
The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types	32
Targeting the histone reader ZMYND8 inhibits antiandrogen-induced neuroendocrine tumor transdifferentiation of prostate cancer	31
Context-dependent tumor-suppressive BMP signaling in diffuse intrinsic pontine glioma regulates stemness through epigenetic regulation of CXXC5	31
The landscape of T cell antigens for cancer immunotherapy	30
Bicarbonate transport as a vulnerability in pancreatic cancer	30
Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer	30
CAR T cell therapy for multiple myeloma	30
Not a generative AI–generated Editorial	30
The growing threat of cyberwarfare in cancer healthcare	30
Checkpoint blockade regulates T cell fate by supporting co-stimulation	30
T cells lead the charge against solid tumors	29
Checking immunotoxicity risks of checkpoint blockade	29
Author Correction: Retargeted oncolytic viruses engineered to remodel the tumor microenvironment for glioblastoma immunotherapy	29
The two sides of the γδ T cell coin	29